/XLO
XLO Stock - Xilio Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$0.67+2.92%
+$0.02 (+2.92%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+946.3%upside
Target: $7.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for XLO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.66 – $0.68
TARGET (TP)$7.00
STOP LOSS$0.62
RISK/REWARD1:129.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.05
52W High$1.70
52W Low$0.61
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $6.34M | N/A | N/A | N/A | N/A |
| Gross Profit | $6.34M | N/A | N/A | $-1,499,000 | $-1,065,000 |
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-60,582,000 | $-79,133,000 | $-89,149,000 | $-75,044,000 | $-54,563,000 |
| Net Income | $-58,241,000 | $-76,404,000 | $-88,222,000 | $-75,800,000 | $-55,219,000 |
| Net Margin | -918.0% | N/A | N/A | N/A | N/A |
| EPS | $-1.09 | $-2.78 | $-3.19 | $-2.72 | $-2.01 |
Company Overview
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$5
Average Target
↑ 572.6% Upside
Now
$2
Low
$5
Average
$7
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 6th 2025 | Leerink Partners | Initiation | Outperform | $2 |
| December 21st 2022 | Chardan Capital Markets | Initiation | Buy | $7 |
Earnings History & Surprises
XLOBeat Rate
36%
Last 14 quarters
Avg Surprise
-118.0%
EPS vs Estimate
Beats / Misses
5/8
1 met exactly
Latest EPS
$-0.03
Q4 2025
EPS Surprise History
Q2 24
-3.2%
$-0.64vs$-0.62
Q2 24
-96.7%
$-0.59vs$-0.30
Q3 24
-4.3%
$-0.24vs$-0.23
Q4 24
+12.0%
$-0.22vs$-0.25
Q1 25
+9.1%
$-0.20vs$-0.22
Q2 25
-280.0%
$-0.18vs$0.10
Q3 25
-100.0%
$-0.16vs$-0.08
Q4 25
0.0%
$-0.03vs$-0.03
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 10, 2026 | $-0.12 | — | — | — |
Q1 2026 | Mar 10, 2026 | $-0.12 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.03 | $-0.03 | 0.0% | = MET |
Q3 2025 | Aug 14, 2025 | $-0.08 | $-0.16 | -100.0% | ✗ MISS |
Q2 2025 | May 8, 2025 | $0.10 | $-0.18 | -280.0% | ✗ MISS |
Q1 2025 | Mar 11, 2025 | $-0.22 | $-0.20 | +9.1% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.25 | $-0.22 | +12.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.23 | $-0.24 | -4.3% | ✗ MISS |
Q2 2024 | May 14, 2024 | $-0.30 | $-0.59 | -96.7% | ✗ MISS |
Q2 2024 | Apr 1, 2024 | $-0.62 | $-0.64 | -3.2% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | — | $-0.78 | — | — |
Q4 2023 | Nov 9, 2023 | $-0.76 | $-0.61 | +19.7% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | — | $-0.70 | — | — |
Q4 2023 | Nov 9, 2023 | — | $-0.79 | — | — |
Q4 2022 | Nov 9, 2022 | $-0.89 | $-0.72 | +19.1% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.78 | $-0.90 | -15.4% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-1.00 | $-0.78 | +22.0% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.94 | $-0.98 | -4.3% | ✗ MISS |
Q4 2021 | Dec 2, 2021 | $-1.60 | $-21.27 | -1229.4% | ✗ MISS |
Q2 2021 | Jun 30, 2021 | — | $-0.87 | — | — |
Latest News
Xilio Therapeutics Q3 EPS $(0.11) Misses $(0.03) Estimate, Sales $19.066M Beat $18.635M Estimate
➖ NeutralBenzinga•Nov 13, 2025, 12:37 PM
Xilio Therapeutics Announces Phase 2 Data For Vilastobart In Combination With Atezolizumab Continues To Demonstrate Differentiated And Generally Well-Tolerated Safety Profile
📈 PositiveBenzinga•Nov 7, 2025, 02:17 PM
Xilio Therapeutics Presents New Data Across Portfolio, Including Preclinical Data Highlighting Potential For Masked T Cell Engager Platform And Programs, As Well As Phase 1 Data For Efarindodekin Alfa, And Phase 2 Data Related To ctDNA For Vilastobart, At SITC 2025
📈 PositiveBenzinga•Nov 7, 2025, 02:14 PM
Xilio Therapeutics Announces It Will Present Late-Breaking Phase 2 Data For Vilastobart At The SITC 40th Annual Meeting Nov 5–9, 2025
📈 PositiveBenzinga•Oct 30, 2025, 01:05 PM
Xilio Therapeutics Hits $17.5M Milestone In Gilead Partnership, Shares New Phase 1 Data On Efarindodekin Alfa
📈 PositiveBenzinga•Sep 9, 2025, 11:43 AM•Also:
Xilio Therapeutics Initiates Patient Dosing In Phase 2 Of An Ongoing Phase 1/2 Clinical Trial Evaluating Efarindodekin Alfa As Monotherapy In Patients With Certain Advanced Solid Tumors
📈 PositiveBenzinga•Sep 9, 2025, 11:37 AM
Xilio Therapeutics announces pricing of $50 million public offering
➖ NeutralSeeking Alpha•Jun 2, 2025, 01:07 PM
Xilio Therapeutics announces public offering; shares down
📉 NegativeSeeking Alpha•Jun 2, 2025, 12:02 PM
Frequently Asked Questions about XLO
What is XLO's current stock price?
Xilio Therapeutics, Inc. (XLO) is currently trading at $0.67 per share. The stock has moved +2.92% today.
What is the analyst price target for XLO?
The average analyst price target for XLO is $7.00, based on 1 analyst.
What sector is Xilio Therapeutics, Inc. in?
Xilio Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is XLO's market cap?
Xilio Therapeutics, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does XLO pay dividends?
No, Xilio Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGS
Aligos Therapeutics, Inc.
$10.68
Mkt Cap: $0.1B
ATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
FGEN
FibroGen, Inc.
$8.60
Mkt Cap: $0.0B
KZR
Kezar Life Sciences, Inc.
$6.34
Mkt Cap: $0.0B
LVTX
LAVA Therapeutics N.V.
$1.74
Mkt Cap: $0.0B
OKUR
OnKure Therapeutics, Inc.
$3.01
Mkt Cap: $0.0B
PDSB
PDS Biotechnology Corporation
$0.89
Mkt Cap: $0.0B
SKYE
Skye Bioscience, Inc.
$0.93
Mkt Cap: $0.0B
TPST
Tempest Therapeutics, Inc.
$3.12
Mkt Cap: $0.0B
TVRD
Tvardi Therapeutics, Inc.
$3.98
Mkt Cap: $0.0B
Explore stocks similar to XLO for comparison